Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service incontinence, prolapse & sacral neuromodulation cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (219 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 31 | 2,199 | 33% |
| 2020 | 18 | 1,457 | 36% |
| 2021 | 19 | 1,688 | 39% |
| 2022 | 26 | 1,895 | 41% |
| 2023 | 27 | 1,939 | 43% |
| 2024 | 26 | 1,784 | 45% |
| 2025 from claims | – | 1,759 1,615–1,862 | 46% |
| 2026 forecast | – | 1,786 1,572–2,061 | 46% |
| 2027 forecast | – | 1,810 1,547–2,156 | 47% |
| 2028 forecast | – | 1,833 1,530–2,245 | 47% |
| 2029 forecast | – | 1,857 1,517–2,329 | 47% |
| 2030 forecast | – | 1,881 1,507–2,410 | 48% |
Slings, artificial sphincter, colpopexy, sacral neuromodulation, penile prosthesis. Professional codes (what the surgeon bills): CPT 57288, 53440, 53445, 57425, 57282, 57283, 64581, 64590, 54405.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 65% of the cases CMS names in New Jersey; 15 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 3% inpatient hospital, 88% hospital outpatient, 9% surgery center. The share outside the hospital has moved +3 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 38 | 3,138−0.8%/yr | −0.8%/yr | 1.7 | 8% | 3,860 in 2030+3.5%/yr |
| Pennsylvania | 45 | 2,928+2.4%/yr | +2.4%/yr | 2.1 | 8% | 3,450 in 2030+2.8%/yr |
| Massachusetts | 30 | 1,885+3.7%/yr | +3.7%/yr | 2.0 | 1% | 2,140 in 2030+2.1%/yr |
| Connecticut | 11 | 668+0.3%/yr | +0.3%/yr | 2.0 | 0% | 740 in 2030+1.6%/yr |
| New Hampshire | 5 | 344−2.3%/yr | −2.3%/yr | 1.5 | 0% | 460 in 2030+4.9%/yr |
| Rhode Island | 2 | 201+0.4%/yr | +0.4%/yr | 2.2 | 31% | 130 in 2030−7.5%/yr |
| Maine | 2 | 101−14%/yr | −14%/yr | 0.6 | 0% | 40 in 2030−13%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 53 | 6,600−1.2%/yr | −1.2%/yr | 6.31.6× | 53% | 5,800 in 2030−2.1%/yr |
| Kidney stone management | 109 | 6,001+1.1%/yr | +1.1%/yr | 5.81.0× | 31% | 7,770 in 2030+4.4%/yr |
| Hysterectomy, hysteroscopy & ablation | 25 | 2,622+0.6%/yr | +0.6%/yr | 2.70.8× | 20% | 3,090 in 2030+2.8%/yr |
| Prostatectomy & nephrectomy | 9 | 867+0.5%/yr | +0.5%/yr | 0.90.7× | 0% | 1,060 in 2030+3.4%/yr |
Incontinence, prolapse & sacral neuromodulation in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with New York
Boston Scientific leads with 57% of company spending on these surgeons in 2025, +5 pts on 2024.
In 2025, 8 companies reported engagement with New Jersey’s surgeons worth $160K in consulting, speaking, meals and travel tied to these products, about $6,154 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 46 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.